In a breakthrough with implications for new therapies, scientists have discovered five groups of prostate cancer, each with different DNA signatures. That discovery means patients may get more customized treatment plans that will try to tackle their subtype. It’s another step toward personalized medicine and a shift from a one-size-fits-all treatment approach. (The Washington Post)